Anti-Ro/SSA-p200 antibodies in the prediction of congenital heart block. An Italian multicentre cross-sectional study on behalf of the 'Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA) Group'
OBJECTIVES: To verify the association between the presence of specific anti-52 Ro/SSA-p200 antibodies and congenital heart block (CHB).
METHODS: 207 pregnant Italian women carrying anti-Ro/SSA Ab were retrospectively evaluated. Anti-p200 Ab were investigated in the mothers' sera by ELISA (Euro-Diagnostica,Wieslab SS-A p200).
RESULTS: CHB occurred in 42 children (34 complete CHB), whereas 165 were not affected. All CHB cases were previously identified with an ELISA screening for anti-Ro/SSA 60 kD Ab. Anti-p200 Ab were more frequently positive (81.0% vs. 59.1%, p=0.013) and at a higher titer in CHB mothers (Absorbance ratio: 2.030 (0.208-4.052) vs. 0.925 (0.200-3.816); p=0.017). This association was maintained even when the 42 mothers of children with CHB were compared with a control group matched for age and diagnosis (80.9% vs. 50.0%; p=0.006). The presence of anti-p200 Ab provided an odds ratio (OR) for CHB of 2.98 (CI: 1.30-6.83), which was higher than that of other variables, such as maternal disease and other antibody specificities. CHB risk significantly decreased in the absence of this fine specificity (OR:0.34, CI: 0.15-0.77). However, while the negative predictive value related to anti-Ro/SSA 60 kD Ab ELISA was 100%, almost 20% of mothers negative for anti-p200 Ab delivered babies with CHB.
CONCLUSIONS: Anti-p200 antibodies seem to be associated with CHB with a higher probability than anti-Ro/SSA Ab, and therefore may be an additional test to identify mothers at higher risk to deliver affected children. An ELISA screening for anti-Ro/SSA 60 kD Ab is nevertheless mandatory given the probability of developing CHB also in the absence of anti-p200 Ab.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Clinical and experimental rheumatology - 32(2014), 6 vom: 14. Nov., Seite 848-54 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Scarsi, Mirko [VerfasserIn] |
|---|
| Themen: |
Antibodies, Antinuclear |
|---|
| Anmerkungen: |
Date Completed 11.03.2015 Date Revised 12.01.2017 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM242903312 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM242903312 | ||
| 003 | DE-627 | ||
| 005 | 20231224131403.0 | ||
| 007 | tu | ||
| 008 | 231224s2014 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0809.xml |
| 035 | |a (DE-627)NLM242903312 | ||
| 035 | |a (NLM)25327946 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Scarsi, Mirko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-Ro/SSA-p200 antibodies in the prediction of congenital heart block. An Italian multicentre cross-sectional study on behalf of the 'Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA) Group' |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2015 | ||
| 500 | |a Date Revised 12.01.2017 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: To verify the association between the presence of specific anti-52 Ro/SSA-p200 antibodies and congenital heart block (CHB) | ||
| 520 | |a METHODS: 207 pregnant Italian women carrying anti-Ro/SSA Ab were retrospectively evaluated. Anti-p200 Ab were investigated in the mothers' sera by ELISA (Euro-Diagnostica,Wieslab SS-A p200) | ||
| 520 | |a RESULTS: CHB occurred in 42 children (34 complete CHB), whereas 165 were not affected. All CHB cases were previously identified with an ELISA screening for anti-Ro/SSA 60 kD Ab. Anti-p200 Ab were more frequently positive (81.0% vs. 59.1%, p=0.013) and at a higher titer in CHB mothers (Absorbance ratio: 2.030 (0.208-4.052) vs. 0.925 (0.200-3.816); p=0.017). This association was maintained even when the 42 mothers of children with CHB were compared with a control group matched for age and diagnosis (80.9% vs. 50.0%; p=0.006). The presence of anti-p200 Ab provided an odds ratio (OR) for CHB of 2.98 (CI: 1.30-6.83), which was higher than that of other variables, such as maternal disease and other antibody specificities. CHB risk significantly decreased in the absence of this fine specificity (OR:0.34, CI: 0.15-0.77). However, while the negative predictive value related to anti-Ro/SSA 60 kD Ab ELISA was 100%, almost 20% of mothers negative for anti-p200 Ab delivered babies with CHB | ||
| 520 | |a CONCLUSIONS: Anti-p200 antibodies seem to be associated with CHB with a higher probability than anti-Ro/SSA Ab, and therefore may be an additional test to identify mothers at higher risk to deliver affected children. An ELISA screening for anti-Ro/SSA 60 kD Ab is nevertheless mandatory given the probability of developing CHB also in the absence of anti-p200 Ab | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 7 | |a Antibodies, Antinuclear |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 650 | 7 | |a Ribonucleoproteins |2 NLM | |
| 650 | 7 | |a SS-A antibodies |2 NLM | |
| 650 | 7 | |a SS-A antigen |2 NLM | |
| 700 | 1 | |a Radice, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Pregnolato, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Ramoni, Veronique |e verfasserin |4 aut | |
| 700 | 1 | |a Grava, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Bianchi, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Gerosa, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Mosca, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Ghirardello, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Tani, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Motta, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Quinzanini, Marzia |e verfasserin |4 aut | |
| 700 | 1 | |a Tincani, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Ruffatti, Amelia |e verfasserin |4 aut | |
| 700 | 1 | |a Migliorini, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Doria, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Meroni, Pier Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Brucato, Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental rheumatology |d 1989 |g 32(2014), 6 vom: 14. Nov., Seite 848-54 |w (DE-627)NLM012613010 |x 0392-856X |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2014 |g number:6 |g day:14 |g month:11 |g pages:848-54 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2014 |e 6 |b 14 |c 11 |h 848-54 | ||